REGN · Q2 2025 Earnings

Cautious

Regeneron Pharmaceuticals

Reported August 1, 2025

30-second summary

EYLEA U.S. fell 39% YoY to $754M while EYLEA HD grew 29% to $393M — not enough to offset the franchise, with combined U.S. retina revenue down 25%. Dupixent (+22% to $4.34B globally, Sanofi-recorded) and Libtayo (+27%) remain the growth engines, but the August PDUFA dates for EYLEA HD label enhancements have slipped due to third-party filler (Catalent) deficiencies that management characterizes as procedural, not structural. Total revenue grew just 4% YoY to $3.68B; the bull case now hinges on Catalent resolution timing and pipeline conversion. Notable guidance moves: GAAP ETR raised to 11–13% (from 9–11%), gross margin guidance trimmed to the low end of the prior range, SG&A and COCM ceilings lowered, and GAAP R&D floor raised.

Headline numbers

EPS

Q2 FY2025

$12.89

Revenue

Q2 FY2025

$3.68B

+4.0% YoY

Gross margin

Q2 FY2025

83.0%

Operating margin

Q2 FY2025

29.4%

Key financials

Q2 FY2025

Metric	Q2 FY2025	YoY
Revenue	$3.68B	+4.0%
EPS	$12.89	—
Gross margin	83.0%	—
Operating margin	29.4%	—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025

Segment	Q2 FY2025	YoY
EYLEA HD - U.S.	$0.393B	+29.0%
EYLEA - U.S.	$0.754B	-39.0%
Total EYLEA HD and EYLEA - U.S.	$1.147B	-25.0%
Libtayo - Global	$0.377B	+27.0%
Dupixent - Global	$4.345B	+22.0%
Praluent - U.S.	$0.066B	+18.0%
Kevzara - Global	$0.152B	+39.0%
Evkeeza - U.S.	$0.041B	+32.0%

Other KPIs

Q2 FY2025

Segment	Q2 FY2025
Dupixent global net sales (Sanofi recorded)	$4.345 billion
EYLEA HD U.S. net sales	$393 million
Total EYLEA (EYLEA HD + EYLEA) U.S. net sales	$1.147 billion
Libtayo global net sales	$377 million
Sanofi collaboration revenue (share of profits)	$1.282 billion
Bayer collaboration revenue (EYLEA ROW)	$383 million
Non-GAAP gross margin on net product sales	86%
R&D expenses as % of revenue	38.7%

Management tone

The press release was the primary input; the transcript supplied substantive Q&A but limited prepared-remarks tone signal. Two cross-cutting observations from the call:

Management's framing of the EYLEA HD Catalent issue was deliberately narrow. Len said the FDA's observations were "not structural changes" requiring a rebuild — "they're mainly process, procedural, those sorts of things" — and stated that Novo Nordisk (Catalent's parent) would file a comprehensive FDA response next week. The confidence is conditional on a third party — Regeneron has minimal direct levers, and the August PDUFA dates for EYLEA HD enhancements have already slipped with no new target date provided. That is a softer position than the unqualified launch optimism that has accompanied prior EYLEA HD updates.

On pipeline valuation, George flagged early myeloma data (100% ORR in an initial linvoseltamab smoldering-myeloma cohort) and said the company anticipates conducting as many as 10 registrational trials for linvoseltamab in a ~$30B myeloma market. The tone was assertive but the evidence is early-stage — management is asking investors to underwrite optionality rather than respond to a near-term catalyst.

On itepekimab, George acknowledged the AERIFY-2 COPD trial missed primary endpoint while AERIFY-1 hit, and said Regeneron and Sanofi continue to evaluate the data to inform next steps for potential future COPD development. No committed path forward was offered. The IL-33 COPD opportunity now reads as a question mark, not a pipeline asset.

Q&A highlights

Tyler Van Buren · TD Cowan

Asked about drivers of ILEA-HD quarter-over-quarter rebound and requested color on the Catalan site inspection issue, including precedent for resolution timeline and potential delays to ILEA-HD approvals.

Marion attributed ILEA-HD growth to physician appreciation for product efficacy, safety, and durability with 16% sequential demand increase. Len indicated the Catalan issues were procedural/process-based rather than structural, with Novo expected to provide robust response expeditiously. Acknowledged limitations in predicting exact timeline but indicated optimism given Novo's commitment and that structural rebuilding not required.

ILEA-HD Q2 net sales: $393 millionILEA-HD unit demand increased 16% sequentiallyCatalan Indiana LLC issues are process/procedural, not structuralNovo Nordisk to file comprehensive FDA response next week

Chris Schott · J.P. Morgan

Asked whether PDUFA delays for ILEA-HD enhancements are purely manufacturing-related or if other FDA issues remain, and inquired about branded share erosion to Avastin and stabilization prospects.

Len confirmed no significant FDA concerns beyond manufacturing issues; expects favorable action once filling is resolved. Marion noted that branded anti-VEGF category volume declined 1.2% due to Avastin uptake driven by affordability issues; Regeneron's total ILEA category share (ILEA + ILEA-HD) remained above 60% in Q2. No clarity provided on share recapture timeline.

Regeneron total ILEA/ILEA-HD branded category share: just over 60%Branded anti-VEGF category volume declined 1.2% in Q2Overall anti-VEGF category volume grew but branded segment declinedAvastin uptake attributed to affordability issues

Akash Tiwari · Jefferies

Asked about impact of Avastin deferred discounts on Pavluo's prolonged run rate and ILEA outlook, and inquired about Regeneron's options to combat Amgen's strategy.

Len acknowledged investigating potential deferred rebate practices by Amgen but avoided commenting on appropriateness. Positioned ILEA-HD as the long-term competitive answer, citing Pavluo's established market presence (100M+ global injections) and manufacturing trust. Confidence in ILEA-HD's superior profile to drive preference once physicians gain experience.

Pavluo globally has ~100 million injections administeredInvestigating whether Amgen using deferred rebatesILEA-HD positioned as primary competitive responseContinued decline in ILEA expected per company guidance

Dave Reisinger · LeeWink Partners

Asked about disconnect between management's optimistic pipeline view (~$5B annual R&D) versus Wall Street's 2032 consensus estimates (~$3.5B), and requested insight into upcoming event path to demonstrate pipeline commercial value.

Len highlighted historical R&D success (Eylea, Dupixent) and directed attention to early myeloma/DLBCL data as evidence of pipeline potential. George elaborated that pipeline valuation concerns may be overstated due to focus on existing mega-product performance; positioned linozific and other programs as potentially industry-defining. Both emphasized 45-program portfolio too large for typical analyst coverage and encouraged detailed review of disclosed data.

Regeneron spends ~$5 billion annually on R&DWall Street consensus 2032 pipeline estimates: ~$3.5 billionPlanned ~8 Phase 3 programs for linozific in myeloma (part of ~$30 billion market)Early myeloma/smoldering myeloma data showing 100% overall response rate in initial cohort

Tim Anderson · Bank of America

Asked whether Len has had frequent visits to Mar-a-Lago with Trump, whether Regeneron has a closer relationship with the administration than competitors, and whether ILEA (Part B drug) could be vulnerable to CMMI demo projects under potential MSN/Medicare pricing initiatives.

Len confirmed frequent visits and acknowledged Trump likely knows Regeneron due to COVID cocktail; declined to claim special policy insights from name-penciling. Stated company agrees with administration that Europeans underpay for innovation but has no unique visibility into MSN policy mechanics. Agreed that solution cannot be U.S. price reductions without European equilibration due to innovation incentive implications.

Len has been to Mar-a-Lago frequentlyRegeneron COVID cocktail may have saved Trump's lifeCompany position: Europeans not paying fair share of innovationNo unique insight into MSN/CMMI demo specifics

What to watch into next quarter

Catalent filling resolution and revised EYLEA HD PDUFA dates — track whether Novo Nordisk's FDA response in early August clears the deficiency and whether FDA issues a new action date for the EYLEA HD label enhancements (extended dosing intervals, pre-filled syringe). Every quarter of delay extends EYLEA U.S. erosion without the offsetting HD ramp.

EYLEA + EYLEA HD U.S. combined revenue trajectory — Q2 combined revenue of $1.147B was down 25% YoY. Watch whether EYLEA HD's +16% QoQ unit demand growth can accelerate enough to stabilize the combined number in Q3, or whether the franchise sets new YoY lows.

Branded anti-VEGF segment dynamics — Regeneron held just above 60% of the branded anti-VEGF segment in Q2 as the branded segment itself shrank 1.2%. Watch whether Regeneron's branded share holds the 60% line and whether the branded segment continues to cede volume to compounded Avastin and Pavblu.

Libtayo adjuvant CSCC approval (October 2025 PDUFA) — a clean approval would meaningfully extend Libtayo's runway and validate a near-term pipeline conversion at a moment when investors are skeptical of the 2032 setup.

Linvoseltamab myeloma readouts — management positioned the smoldering myeloma and DLBCL data as the principal pipeline-value catalyst. Watch for the next data drop and Phase 3 initiation pace against management's stated target of as many as 10 registrational trials.

Itepekimab COPD path — whether management commits to a third COPD trial or deprioritizes IL-33 in COPD after the AERIFY-2 miss; an exit would shrink the pipeline tail.

Sources

Regeneron Q2 2025 press release (Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm
Regeneron Q2 2025 earnings call Q&A (transcript-derived)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.